66 related articles for article (PubMed ID: 38577447)
1. Impact of Nutritional Status on Neutrophil-to-Lymphocyte Ratio as a Predictor of Efficacy and Adverse Events of Immune Check-Point Inhibitors.
Sue M; Takeuchi Y; Hirata S; Takaki A; Otsuka M
Cancers (Basel); 2024 May; 16(10):. PubMed ID: 38791890
[TBL] [Abstract][Full Text] [Related]
2. Independent predictive value of blood inflammatory composite markers in ovarian cancer: recent clinical evidence and perspective focusing on NLR and PLR.
Zhang CL; Jiang XC; Li Y; Pan X; Gao MQ; Chen Y; Pang B
J Ovarian Res; 2023 Feb; 16(1):36. PubMed ID: 36759864
[TBL] [Abstract][Full Text] [Related]
3. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio: Markers predicting immune-checkpoint inhibitor efficacy and immune-related adverse events.
Jiang QY; Xue RY
World J Gastrointest Oncol; 2024 Mar; 16(3):577-582. PubMed ID: 38577447
[TBL] [Abstract][Full Text] [Related]
4. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
Pavan A; Calvetti L; Dal Maso A; Attili I; Del Bianco P; Pasello G; Guarneri V; Aprile G; Conte P; Bonanno L
Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312
[TBL] [Abstract][Full Text] [Related]
5. Neutrophil-to-Lymphocyte Ratio Predicts Development of Immune-Related Adverse Events and Outcomes from Immune Checkpoint Blockade: A Case-Control Study.
Lee PY; Oen KQX; Lim GRS; Hartono JL; Muthiah M; Huang DQ; Teo FSW; Li AY; Mak A; Chandran NS; Tan CL; Yang P; Tai ES; Ng KWP; Vijayan J; Chan YC; Tan LL; Lee MB; Chua HR; Hong WZ; Yap ES; Lim DK; Yuen YS; Chan YH; Aminkeng F; Wong ASC; Huang Y; Tay SH
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33804050
[TBL] [Abstract][Full Text] [Related]
6. Peripheral Blood Markers Associated with Immune-Related Adverse Effects in Patients Who Had Advanced Non-Small Cell Lung Cancer Treated with PD-1 Inhibitors.
Liu W; Liu Y; Ma F; Sun B; Wang Y; Luo J; Liu M; Luo Z
Cancer Manag Res; 2021; 13():765-771. PubMed ID: 33536784
[TBL] [Abstract][Full Text] [Related]
7. Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as potential predictive markers of treatment response in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
Rugambwa TK; Abdihamid O; Zhang X; Peng Y; Cai C; Shen H; Zeng S; Qiu W
Front Oncol; 2023; 13():1181248. PubMed ID: 38023176
[TBL] [Abstract][Full Text] [Related]
8. Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma.
Dharmapuri S; Özbek U; Jethra H; Jun T; Marron TU; Saeed A; Huang YH; Muzaffar M; Pinter M; Balcar L; Fulgenzi C; Amara S; Weinmann A; Personeni N; Scheiner B; Pressiani T; Navaid M; Bengsch B; Paul S; Khan U; Bettinger D; Nishida N; Mohamed YI; Vogel A; Gampa A; Korolewicz J; Cammarota A; Kaseb A; Galle PR; Pillai A; Wang YH; Cortellini A; Kudo M; D'Alessio A; Rimassa L; Pinato DJ; Ang C
World J Gastrointest Oncol; 2023 Nov; 15(11):1900-1912. PubMed ID: 38077640
[TBL] [Abstract][Full Text] [Related]
9. CD36-BATF2\MYB Axis Predicts Anti-PD-1 Immunotherapy Response in Gastric Cancer.
Jiang Q; Chen Z; Meng F; Zhang H; Chen H; Xue J; Shen X; Liu T; Dong L; Zhang S; Xue R
Int J Biol Sci; 2023; 19(14):4476-4492. PubMed ID: 37781029
[TBL] [Abstract][Full Text] [Related]
10. Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab.
Wu YL; Fulgenzi CAM; D'Alessio A; Cheon J; Nishida N; Saeed A; Wietharn B; Cammarota A; Pressiani T; Personeni N; Pinter M; Scheiner B; Balcar L; Huang YH; Phen S; Naqash AR; Vivaldi C; Salani F; Masi G; Bettinger D; Vogel A; Schönlein M; von Felden J; Schulze K; Wege H; Galle PR; Kudo M; Rimassa L; Singal AG; Sharma R; Cortellini A; Gaillard VE; Chon HJ; Pinato DJ; Ang C
Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497316
[TBL] [Abstract][Full Text] [Related]
11. Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio as Prognostic Markers for Advanced Non-Small-Cell Lung Cancer Treated with Immunotherapy: A Systematic Review and Meta-Analysis.
Platini H; Ferdinand E; Kohar K; Prayogo SA; Amirah S; Komariah M; Maulana S
Medicina (Kaunas); 2022 Aug; 58(8):. PubMed ID: 36013536
[TBL] [Abstract][Full Text] [Related]
12. Platelet-to-lymphocyte and neutrophil-to-lymphocyte ratios are associated with the efficacy of immunotherapy in stage III/IV non-small cell lung cancer.
Lu X; Wan J; Shi H
Oncol Lett; 2022 Aug; 24(2):266. PubMed ID: 35782904
[TBL] [Abstract][Full Text] [Related]
13. Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1.
McCulloch JA; Davar D; Rodrigues RR; Badger JH; Fang JR; Cole AM; Balaji AK; Vetizou M; Prescott SM; Fernandes MR; Costa RGF; Yuan W; Salcedo R; Bahadiroglu E; Roy S; DeBlasio RN; Morrison RM; Chauvin JM; Ding Q; Zidi B; Lowin A; Chakka S; Gao W; Pagliano O; Ernst SJ; Rose A; Newman NK; Morgun A; Zarour HM; Trinchieri G; Dzutsev AK
Nat Med; 2022 Mar; 28(3):545-556. PubMed ID: 35228752
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
